A phase III study of trofinetide in patients with Rett syndrome
Phase of Trial: Phase III
Latest Information Update: 22 Mar 2017
At a glance
- Drugs Trofinetide (Primary)
- Indications Rett syndrome
- Focus Registrational; Therapeutic Use
- Sponsors Neuren Pharmaceuticals
- 22 Mar 2017 According to a Neuren Pharmaceuticals media release, company intends to discuss the plans related to this trial, which is expected to begin in 2018, with the US FDA.
- 04 Jan 2016 This trial is expected to begin in 2017, according to a Neuren Pharmaceuticals media release.
- 04 Aug 2015 New trial record